ALNY Q4 2021 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$259M+58.1% YoY

Gross Profit

$221M85.4% margin

Operating Income

-$195M-75.3% margin

Net Income

-$258M-100.0% margin

EPS (Diluted)

$-2.16

QoQ Revenue Growth

+37.8%

Cash Flow

Operating Cash Flow

-$150M

Free Cash Flow

-$172M

Stock-Based Comp.

$45M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$3.1B

Stockholders' Equity

$588M

Cash & Equivalents

$820M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$259M	$164M	+58.1%
Gross Profit	$221M	$141M	+57.2%
Operating Income	-$195M	-$194M	-0.2%
Net Income	-$258M	-$244M	-6.1%

Revenue Segments

Product

$199M100%

Royalty

$396,0000%

Geographic Segments

Non-US Or Europe

$25M59%

Europe

$12M28%

UNITED STATES

$6M14%